Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia
Blood Podcast
00:00
BRAF V600E Mutation Positive HCL
The study enrolled 55 patients with BRAF V600E mutation positive HCL. All patients had relapsed or progressed after treatment with purine analogs, either pentastatin or claudrybean. Most patients had received at least two prior lines of therapy. The investigator assessed ORR was 89.1%, 65.5% of patients had a complete response, and 23.6%.
Transcript
Play full episode
